Medtronic
(NYSE: MDT)
announced today that it received CE mark approval for its new Simplera continuous glucose monitor (CGM).
The all-in-one, disposable CGM features a simple, two-step insertion process for people with diabetes using multiple daily injections (MDI). Medtronic’s newest no-fingerstick sensor eliminates the need for overtape, too. It seamlessly integrates with the InPen smart insulin pen for real-time, personalized dosing guidance to simplify diabetes management.
Medtronic plans to begin a phased launch for Simplera at the European Association for the Study of Diabetes (EASD) 59th Annual Meeting. It takes place in Hamburg, Germany, from Oct. 2-6.
Commercializing a new CGM comes at a good time for Medtronic, which could see the benefits from the newly popular GLP-1 drug class. Analysts recently outlined the ways in which those drugs may provide a boom for the CGM market.
Get the full story at our sister site, Drug Delivery Business News.